Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events.

[1]  G. Hankey,et al.  Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.

[2]  D. Agrawal,et al.  Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition. , 2020, Translational research : the journal of laboratory and clinical medicine.

[3]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[4]  P. Libby,et al.  From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[5]  A. von Eckardstein,et al.  Inflammation during acute coronary syndromes - Risk of cardiovascular events and bleeding. , 2019, International journal of cardiology.

[6]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[7]  Samin K. Sharma,et al.  Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions , 2018, European heart journal.

[8]  A. von Eckardstein,et al.  Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score , 2018, European heart journal. Acute cardiovascular care.

[9]  A. Akhmedov,et al.  Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes , 2017, European heart journal.

[10]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[11]  P. Ridker.  How Common Is Residual Inflammatory Risk? , 2017, Circulation research.

[12]  Paul M Ridker,et al.  Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. , 2016, European heart journal.

[13]  P. Ridker.  From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[14]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[15]  L. Räber,et al.  Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland , 2015, Heart.

[16]  L. Räber,et al.  Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. , 2015, Atherosclerosis.

[17]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[18]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, JAMA.

[19]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .